Day One Biopharmaceuticals Inc (NASDAQ:DAWN) has a beta value of -1.49 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $1.21B, closed the last trade at $13.80 per share which meant it lost -$0.13 on the day or -0.93% during that session. The DAWN stock price is -35.29% off its 52-week high price of $18.67 and 29.93% above the 52-week low of $9.67. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.96 million shares traded. The 3-month trading volume is 556.79K shares.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) trade information
Sporting -0.93% in the red in last session, the stock has traded in the red over the last five days, when the DAWN stock price touched $13.80 or saw a rise of 7.88%. Year-to-date, Day One Biopharmaceuticals Inc shares have moved -5.48%, while the 5-day performance has seen it change -6.31%. Over the past 30 days, the shares of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) have changed -9.98%. Short interest in the company has seen 9.7 million shares shorted with days to cover at 20.96.
Day One Biopharmaceuticals Inc (DAWN) estimates and forecasts
Figures show that Day One Biopharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -1.71% over the past 6 months, with this year growth rate of -12.24%, compared to 12.40% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -11.90% and -9.80% for the next quarter.
6 have an estimated revenue figure of $570k for the next quarter concluding in Jun 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -84.59% over the past 5 years.
DAWN Dividends
Day One Biopharmaceuticals Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Day One Biopharmaceuticals Inc (NASDAQ:DAWN)’s Major holders
Insiders own 19.71% of the company shares, while shares held by institutions stand at 89.06% with a share float percentage of 110.92%. Investors are also buoyed by the number of investors in a company, with Day One Biopharmaceuticals Inc having a total of 212 institutions that hold shares in the company. The top two institutional holders are RA Capital Management, L.P. with over 7.81 million shares worth more than $93.25 million. As of Jun 29, 2023, RA Capital Management, L.P. held 8.98% of shares outstanding.
The other major institutional holder is Atlas Venture Life Science Advisors, LLC, with the holding of over 7.61 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $90.84 million and represent 8.75% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Aug 30, 2023, the former fund manager holds about 2.82% shares in the company for having 2.45 million shares of worth $33.07 million while later fund manager owns 1.86 million shares of worth $22.17 million as of Jun 29, 2023, which makes it owner of about 2.14% of company’s outstanding stock.
